
Deal Flow Quality beats “picking skill” The figure below is a reminder that most VC chest-thumping is aimed at the wrong variable. In venture, outcomes are driven by two levers: >Pool quality (base rate): how many real winners exist in what you see >Picking skill (accuracy): how well you separate winners from noise When the pool is weak, even strong investors are forced into false positives. The signal is too thin. Better judgment helps, but it hits a ceiling fast. The chart makes the point visually: >A small improvement in pool quality drives a big jump in portfolio hit rate >Even a large improvement in picking skill moves the needle less Reason is simple Bayes. Pool quality sets the prior. Picking skill only works inside that constraint. You can’t select winners that aren’t in your universe. So “proprietary dealflow” is not a flex. It’s the job. Alpha is upstream of everything, better origination, better timing, better information flow. If you want higher hit rates, start with a better pool.

🧨 5 Potential Black Swan Biotech Events in 2026 Low probability. Massive impact. Worth thinking about. 😲Multiple deaths from incorrect AI health advice One high-profile event could trigger lawsuits, regulation, and an overnight sentiment flip on AI-in-healthcare. 😲Sudden safety, supply, or reimbursement shock...

Predictions for the future of AI - the one that catches my attn most is the $5 copay Today; You wake up with a sore throat and grab the first primary care slot you can find. Ten minutes with a rushed clinician...

A few key takeaways from this week’s top biotech news: $BMY & $JANX: Tackling T-cell toxicity with tumor-activated masks. $PFE & $NVAX: Diversifying beyond mRNA for strategic risk hedging. $JNJ: projecting >$100B revenue post-Stelara patent cliff. $RHHBY: Building manufacturing moats for obesity market dominance. FDA:...

Phase I AI-discovered molecules show an 80-90% success rate in Ph1-to-Ph2 transition. *vs historic benchmark ~50% https://t.co/rC03gNjOPo https://t.co/AcK2XxfrW0

Great progress update on the war on cancer “GBM, colorectal and liver still look very challenging...” See below for detail point down 👇🏼 https://t.co/UTFZSsDVcX

$CORT +30% pre-market Still room to run? >OS met: HR 0.65 (-35% death risk), mOS 16.0 vs 11.9 mo (+4.1) >PFS (prior): HR 0.70 (-30%) >n=381, safety ≈ control, no biomarker needed What’s next: full dataset at a med meeting; FDA PDUFA Jul 11, 2026...

$CRVS +57% premarket on AD Cohort-4: randomized PBO-controlled signal (EASI-75 75%, mean EASI −72% vs −40% PBO; p=0.035) with clean safety, real but fragile (n=12 vs 12; 10 PBO-evaluable). 📝No skin-biopsy disclosed. While exiting progress serum PD != tissue reversal....

We asked the biotwit some interesting industry questions. The answers were telling... 5 takeaways from last week’s biotech polls: 1️⃣ When efficacy ceilings are hit, risk wins. Safety, tolerability, and long-term risk profile now beat novelty and precision once drugs work “well enough.” 2️⃣...

$IBRX is trending on the TL - but the +40% pop more likely driven by prelim 2025 net product revenue of ~$113M, up ~700% y/y and not this tiny N CD19 CAR-NK + ritux anecdote in a rare lymphoma. https://t.co/64wkMTGX9v
The Mega-Fund Math vs Reality Below is a simple case study on fund math. People are asking if a16z can really do a 3-5x on a $15B fund. To 3x net on $15B, you need ~$45B back. Assume ~5% ownership at exit. 👉 That...
Which modality has the cleanest path to durable clinical value over the next 5 years?
1/ The Back Door Is Open How Acute Infection Could Make Anti-Infectives Investable Again Anti-infectives never died. The business model did. Low prices. Short courses. High resistance risk. Pharma walked. Now look at Alfasigma stepping into HSV encephalitis. Small deal. Narrow indication. Big implication....
Nice ALS market map 👇 When precision approaches go broad….looks like yes that can happen. “…a third category being overlooked: 28 programs that are genetically informed but not mutation-restricted. Examples: drugs targeting TDP-43 protein clumps or repeat RNA toxicity. These mechanisms...

PD(L1)xVEGF the Keytruda replacement? The deal making market is clearly not pricing it that way. 🗣️“We want exposure to a hot mechanism, but we want most of the price contingent on Phase 2/3 and commercial proof.” Great analysis below...

👀 Real precision medicine from $AZN $DSNKY TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer “…TROPION-Lung17 is the first phase 3 clinical trial to prospectively enroll patients with tumors...
Good dialog - worth the 3.5min listen 👂 TLDR - investors do not like uncertainty. Macro uncertainty, technical uncertainty, commercial uncertainty. Remove uncertainty and number go up $XBI

Expect BIG activity from pharma with PD1xVEGF combos… $SMMT Announces Clinical Trial Collaboration with $GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) $PFE has already telegraphed (and started to operationalize) the same playbook. https://t.co/JTY2cuJtMG https://t.co/0zCI8zFouB
The Next Generation of Multi-Functional I&I Therapeutics | Ep. 903 How to Pick Winners From a Crowded Cytokine War Bispecifics are everywhere, China biotech is running every combo possible including the ones you have not thought of yet. Trispecifics are next, and...

1/ 💡While much of the immunology field is fixated on immune reset in B cells and autoimmunity, a quieter version of the same idea is emerging in cardio-immunology. 🫀 Except we are not talking about lymphocytes. This is all about tissue-resident macrophages. And...
Your Weekly Biotech News Fix | Ep. 901 Designed to be consumed as a quick scroll 🧬 Parabilis - $305M Wnt bet 🔥 $LLY - Buys $VTYX (NLRP3) 🎯 $PFE - Cartography antigen deal 🧲 $AMGN - Dark Blue acquisition 🦠 $GSK / $IONS - HBV...

$ASND -2.5% Looks approvable (priority review; class precedent). Combo = upside optionality, not the label. COACH Wk-52 open-label Ph2 (n=21) CNP + hGH >AGV: 8.8 (naïve) / 8.42 cm/yr (prior-CNP), >97th pct vs avg-stature >Z-score: +1.02 / +0.86; proportionality/arm-span up; bone age “consistent” >AEs...

$QURE +13% uniQure Announces Type A Meeting Scheduled with FDA 🍿 uniQure Announces Type A Meeting Scheduled with FDA https://t.co/iqZkaNYD7Z https://t.co/lRcR6vgV0D

$KYRS +1% Nice science, market not convinced. KB407 shows delivery + CFTR protein in bronchoscopic biopsies, but no sweat chloride/NPD/FEV1. End of day, PD != clinical translation. Also a crowded CF GTx race = priced in. $FDMT 4D-710 (ppFEV1/LCI signals),...

JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...
From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...

$GLUE +45% MRT-8102 delivers eye-catching 4-week biomarker win with clean early safety and the convenience of an oral approach. MRT-8102 degrades NEK7, a scaffolding protein essential for NLRP3 inflammasome assembly, shutting down upstream activation of IL-1β/IL-18 and downstream IL-6/hsCRP, which...